Targeted therapies: Glioma-it's all in the site occupancy

Nature Reviews Clinical Oncology

Volumn 9, Issue 6, 2012, Pages 308-

  Hutchinson, Lisa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LAPATINIB; NERATINIB;

BRAIN TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG RELEASE; EGFR GENE; ENZYME ACTIVE SITE; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG CANCER; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84861718902     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.65     Document Type: Note

References (2)

1. Vivanco, I. et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. doi:10.1158/2159-8290.CD-11-0284
2. Barkovich, K. J. et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov. doi:10.1158/2159-8290.CD-11-0287